Literature DB >> 11083818

Genetically determined disparate innate and adaptive cell-mediated immune responses to pulmonary Mycobacterium bovis BCG infection in C57BL/6 and BALB/c mice.

J Wakeham1, J Wang, Z Xing.   

Abstract

The current study was designed to investigate the impact of genetic heterogeneity on host immune responses to pulmonary intracellular infection by using two mouse strains of distinct genetic background, C57BL/6 and BALB/c mice, and a model intracellular pathogen, Mycobacterium bovis BCG. Upon infection, compared to C57BL/6 mice, BALB/c mice developed an earlier response of interleukin 12 (IL-12), gamma interferon (IFN-gamma), tumor necrosis factor alpha, and macrophage chemoattractive protein 1, and greater neutrophilic influx to the lung by days 7 and 14. However, the level of these cytokines at days 27, 43, and 71 was much lower in BALB/c mice than in C57BL/6 mice. The magnitude of cellular responses was also much lower in the lung of BALB/c mice around day 27. Histologically, while C57BL/6 mice developed lymphocytic granulomas, BALB/c mice displayed atypical granulomas in the lung. Of importance, the level of type 2 cytokines IL-4 and IL-10 remained low and similar in the lung of both C57BL/6 and BALB/c mice throughout. Furthermore, lymphocytes isolated from systemic and local lymphoid tissues of infected BALB/c mice demonstrated a markedly lower antigen-specific IFN-gamma recall response. While the number of mycobacterial bacilli recovered from both the lung and spleen of BALB/c mice was similar to that in C57BL/6 mice at day 14, it was higher than that in C57BL/6 mice at day 43. However, it was eventually leveled off to that in C57BL/6 counterparts later. These results suggest the following: (i) genetic heterogeneity can lead to differential innate and adaptive cell-mediated immune responses to primary pulmonary mycobacterial infection; (ii) it is the level of adaptive, but not innate, immune response that is critical to host resistance; and (iii) a lower type 1 immune response in BALB/c mice is not accompanied by a heightened type 2 response during pulmonary mycobacterial infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11083818      PMCID: PMC97803          DOI: 10.1128/IAI.68.12.6946-6953.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

1.  Interleukin-4 and interleukin-10 synergize to inhibit cell-mediated immunity in vivo.

Authors:  F Powrie; S Menon; R L Coffman
Journal:  Eur J Immunol       Date:  1993-09       Impact factor: 5.532

2.  Macrophages are a significant source of type 1 cytokines during mycobacterial infection.

Authors:  J Wang; J Wakeham; R Harkness; Z Xing
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

3.  Spleen cell cytokine secretion in Mycobacterium bovis BCG-infected mice.

Authors:  K Huygen; D Abramowicz; P Vandenbussche; F Jacobs; J De Bruyn; A Kentos; A Drowart; J P Van Vooren; M Goldman
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

4.  Dissection of strain difference in acquired protective immunity against Mycobacterium bovis Calmette-Guérin bacillus (BCG). Macrophages regulate the susceptibility through cytokine network and the induction of nitric oxide synthase.

Authors:  A Yoshida; Y Koide; M Uchijima; T O Yoshida
Journal:  J Immunol       Date:  1995-08-15       Impact factor: 5.422

5.  Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice.

Authors:  J L Flynn; M M Goldstein; J Chan; K J Triebold; K Pfeffer; C J Lowenstein; R Schreiber; T W Mak; B R Bloom
Journal:  Immunity       Date:  1995-06       Impact factor: 31.745

6.  Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis.

Authors:  G D Miralles; M Y Stoeckle; D F McDermott; F D Finkelman; H W Murray
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

Review 7.  T cell response to Mycobacterium tuberculosis.

Authors:  I M Orme; P Andersen; W H Boom
Journal:  J Infect Dis       Date:  1993-06       Impact factor: 5.226

8.  Early gamma interferon mRNA expression is associated with resistance of mice against Yersinia enterocolitica.

Authors:  E Bohn; J Heesemann; S Ehlers; I B Autenrieth
Journal:  Infect Immun       Date:  1994-07       Impact factor: 3.441

9.  Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha.

Authors:  I E Flesch; J H Hess; S Huang; M Aguet; J Rothe; H Bluethmann; S H Kaufmann
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

10.  Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets.

Authors:  F P Heinzel; M D Sadick; B J Holaday; R L Coffman; R M Locksley
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more
  26 in total

1.  Hypercholesterolemia induces T cell expansion in humanized immune mice.

Authors:  Jonathan D Proto; Amanda C Doran; Manikandan Subramanian; Hui Wang; Mingyou Zhang; Erdi Sozen; Christina C Rymond; George Kuriakose; Vivette D'Agati; Robert Winchester; Megan Sykes; Yong-Guang Yang; Ira Tabas
Journal:  J Clin Invest       Date:  2018-04-30       Impact factor: 14.808

2.  BCG sub-strains induce variable protection against virulent pulmonary Mycobacterium tuberculosis infection, with the capacity to drive Th2 immunity.

Authors:  Andrew Keyser; Jolynn M Troudt; Jennifer L Taylor; Angelo A Izzo
Journal:  Vaccine       Date:  2011-10-18       Impact factor: 3.641

3.  Pulmonary M. tuberculosis infection delays Th1 immunity via immunoadaptor DAP12-regulated IRAK-M and IL-10 expression in antigen-presenting cells.

Authors:  M Jeyanathan; S McCormick; R Lai; S Afkhami; C R Shaler; C N Horvath; D Damjanovic; A Zganiacz; N Barra; A Ashkar; M Jordana; N Aoki; Z Xing
Journal:  Mucosal Immunol       Date:  2013-10-30       Impact factor: 7.313

4.  Mycobacterium-induced potentiation of type 1 immune responses and protection against malaria are host specific.

Authors:  Kathleen R Page; Anne E Jedlicka; Benjamin Fakheri; Gregory S Noland; Anup K Kesavan; Alan L Scott; Nirbhay Kumar; Yukari C Manabe
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

5.  Lactation-Based Maternal Educational Immunity Crosses MHC Class I Barriers and Can Impart Th1 Immunity to Th2-Biased Recipients.

Authors:  Mrinal K Ghosh; H Konrad Muller; Ameae M Walker
Journal:  J Immunol       Date:  2017-07-26       Impact factor: 5.422

6.  Pulmonary Mycobacterium bovis BCG vaccination confers dose-dependent superior protection compared to that of subcutaneous vaccination.

Authors:  Nacho Aguilo; Ana Maria Toledo; Eva Maria Lopez-Roman; Esther Perez-Herran; Eamonn Gormley; Joaquin Rullas-Trincado; Iñigo Angulo-Barturen; Carlos Martin
Journal:  Clin Vaccine Immunol       Date:  2014-02-05

7.  Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis.

Authors:  Lihao Chen; Jun Wang; Anna Zganiacz; Zhou Xing
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

8.  Differential activation of the immune system by virulent Streptococcus pneumoniae strains determines recovery or death of the host.

Authors:  Y Mizrachi-Nebenzahl; S Lifshitz; R Teitelbaum; S Novick; A Levi; D Benharroch; E Ling; R Dagan
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

9.  Differential regulation of DAP12 and molecules associated with DAP12 during host responses to mycobacterial infection.

Authors:  Naoko Aoki; Anna Zganiacz; Peter Margetts; Zhou Xing
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

10.  Immune-mediated anti-neoplastic effect of intratumoral RSV envelope glycoprotein expression is related to apoptotic death of tumor cells but not to the size of syncytia.

Authors:  Dennis Hoffmann; Thomas Grunwald; Wibke Bayer; Oliver Wildner
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.